Solvay has selected the Bionas® 2500 analyzing system because it allows monitoring of both acute (short-term) and chronic (long-term) effects of drug candidates in different cell types thanks to a proprietary perfusion system. Besides the long-term observation of cells under close to in vivo conditions, the observation of regeneration effects is also possible.
"The Bionas instrument is a valuable tool for compound ranking and helps us select the most promising compounds for further development," says Dr. Michael Firnges at Solvay Pharmaceuticals GmbH.
The Bionas® 2500 analyzing system is a bench-top instrument that allows the simultaneous, label-free and high-content analysis of three metabolic parameters, such as acidification, oxygen consumption and adhesion of living cells. The Bionas instrument has been also se-lected by Solvay Pharmaceuticals Research Laboratories (Weesp, Netherlands) for target validation studies.
Kontakt:
Dr. Michael Schulze
Bionas GmbH
Phone: +49 (0) 381 5196-241
Email: michael.schulze@bionas.de
Web: www.bionas.de